marked.bio

anti-VEGF antibody · antibody

bevacizumab

82 active trials across 16 of our biomarkers, targeting VEGF-A. 2 active approvals for a biomarker on marked.bio.

Also known as Avastin.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Approvals and pivotal results

Biomarker-selected approvals in the United States and the European Union, with the pivotal trial's results and side effects where we have them. Results from different trials are not directly comparable.

TherapyBiomarkerTumourUnited StatesEuropean Union
olaparib with bevacizumab
FDA, 2020
first-line maintenance, advanced ovarian cancer in response to platinum, HRD-positive (deleterious BRCA mutation and/or genomic instability) Current label 1.2. Year (reported May 2020) not checked against an FDA announcement. Year confirmed: FDA approval announced 08/05/2020. Source
EU (EMA), 2020
first-line maintenance, advanced high-grade ovarian cancer in response after platinum + bevacizumab, HRD-positive (BRCA1/2 mutation and/or genomic instability) II/0035, EC decision 03/11/2020. HRD-positive includes BRCA1/2-mutated (broad). Source
LynparzaBroader labelolaparib page 		BRCA1/2 mutation ovarian Approved 2020 Approved 2020

In the US label

PAOLA-1 (HRD-positive) vs placebo + bevacizumab, 255 vs 132 patients
PFS 37.2 months vs 17.7 months, HR 0.33 (0.25-0.45)

Serious side effects 31%Stopped for side effects 20%

Trial details and side effects
Patients
first-line maintenance, HRD-positive advanced ovarian cancer, with bevacizumab (NCT02477644)
Most common side effects
fatigue 53%, nausea 53%, anaemia 41%, lymphopenia 24%, vomiting 22% (535 patients)
Notes
HRD-positive includes BRCA mutation. Lynparza US label.
Source
US label

In the EU product information

PAOLA-1 (HRD-positive) vs placebo + bevacizumab, 255 vs 132 patients
PFS 37.2 months vs 17.7 months, HR 0.33 (0.25-0.45)OS HR 0.62 (0.45-0.85)

Trial details and side effects
Patients
first-line maintenance, HRD-positive advanced ovarian cancer, with bevacizumab (NCT02477644)
Most common side effects
fatigue 53%, nausea 53%, anaemia 41%, lymphopenia 24%, vomiting 22% (535 patients)
Notes
EU SmPC section 5.1 (PAOLA-1 HRD-positive subgroup). Side effects from the US label.
Source
EU product information

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 22 43 Phase 3
EGFR exon 19 deletion / L858R 20 54 Phase 2
KRAS G12D 18 39 Phase 3
BRAF V600E 14 20 Phase 3
BRCA1/2 mutation 11 15 Phase 3
MSI-H / dMMR 9 16 Phase 3
ALK fusion 8 18 Phase 2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 3 4 Phase 2
EGFR exon 20 insertion 1 2 Phase 2
HER2 (ERBB2) activating mutation 1 1 Phase 2
IDH1/2 mutation 1 1 Phase 3
PIK3CA activating mutation 1 3 Phase 1
RET fusion or mutation 1 1 Phase 2
ROS1 fusion 1 2 Phase 2
FGFR2 fusion or rearrangement 0 1 –
MET exon 14 skipping 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of bevacizumab.

  1. Genmab 3
  2. AstraZeneca 2
  3. MSD (Merck & Co.) 2
  4. Pfizer 2
  5. GSK 2
  6. Innovent Biologics 1
  7. Dizal Pharmaceuticals 1
  8. Amgen 1
  9. Roche 1
  10. Luye Pharma Group 1
  11. Oncolytics Biotech 1
  12. BOE Technology Group 1

Trials

82 of 167 trials shown

  1. Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)

    Not yet recruiting Phase 3 Fudan University Started 2026Primary completion 2028-12 NCT07362836

    fruquintinibbevacizumab

    RAS mutant type.

    KRAS G12CKRAS G12DColorectal Cancer

  2. A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

    Recruiting Phase 3 GSK Started 2026Primary completion 2030-05 NCT07684612

    Mocertatug rezetecan (Mo-Rez)carboplatinpaclitaxelgemcitabinepegylated liposomal doxorubicinbevacizumab FDA EU

    …al testing (compliant to local regulations) for tumor and/or germline Breast Cancer Gene (BRCA1 and BRCA2) mutation.

    BRCA1/2 mutationOvarian Neoplasms

  3. Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

    Recruiting Phase 3 Genmab Started 2026Primary completion 2029-12 NCT07564141

    rinatabart sesutecanbevacizumab FDA EUcarboplatingemcitabinepaclitaxelpegylated liposomal doxorubicin

    …cizumab) is required for participants with breast cancer susceptibility gene (BRCA 1- and BRCA 2)-mutated (germline or somatic) or homologous recombination deficiency (HRD)-positive disease.

    BRCA1/2 mutationPlatinum-Sensitive Ovarian Cancer, Ovarian Cancer

  4. A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

    Recruiting Phase 3 GSK Started 2026Primary completion 2030-07 NCT07286266

    Mocertatug rezetecanpaclitaxelpegylated liposomal doxorubicintopotecangemcitabinepembrolizumabbevacizumab FDA EU

    PARPi, in participants with known or suspected deleterious germline or somatic BRCA mutations and who achieved a complete or partial response to platinum-based chemotherapy must have …

    BRCA1/2 mutationOvarian Neoplasms

  5. Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

    Recruiting Phase 3 Genmab Started 2026Primary completion 2028-10 NCT07225270

    rinatabart sesutecanbevacizumab FDA EU

    Participants with known breast cancer (BRCA)-mutated (somatic or germline) or homologous recombination deficiency (HRD)-positive ovarian cance…

    BRCA1/2 mutationOvarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC

  6. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    Recruiting Phase 3 MSD (Merck & Co.) Started 2025Primary completion 2029-03 NCT06997497

    calderasiboxaliplatinleucovorinfluorouracilcetuximabbevacizumab

    Demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation

    KRAS G12CColon Adenocarcinoma, Rectal Adenocarcinoma

  7. Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

    Recruiting Phase 3 University of Campania Luigi Vanvitelli Started 2025Primary completion 2030-10 NCT07389265

    cetuximab FDA EUbevacizumabFOLFOXleucovorinfluorouraciloxaliplatinFOLFIRIirinotecan

    RAS (NRAS and KRAS exon 2,3 and 4), BRAFV600E, PIK3CA, EGFR ECD wild-type and HER2 not amplified in liquid biopsy at the time of screen…

    BRAF V600EMetastatic Colorectal Cancer (mCRC)

  8. Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

    Recruiting Phase 3 NRG Oncology Started 2025Primary completion 2034-12 NCT06580314

    bevacizumab FDA EUolaparib FDA EU

    Other epithelial ovarian cancer with BRCA1/2 deleterious alteration (germline or somatic), (excluding tumors that are known mismatch repair defici…

    BRCA1/2 mutationMSI-H / dMMRFallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014

  9. Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

    Recruiting Phase 3 The Netherlands Cancer Institute Started 2025Primary completion 2028-07 NCT06888817

    bevacizumabdexamethasone

    …osis of high-grade diffuse glioma according to WHO 2021 criteria, including: astrocytoma, IDH-mutant, grade 3-4

    IDH1/2 mutationRadiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity

  10. Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

    Recruiting Phase 3 Amgen Started 2024Primary completion 2028-09 NCT06252649

    FOLFIRIsotorasib FDA EUpanitumumab FDAbevacizumab

    Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.

    KRAS G12CMetastatic Colorectal Cancer

  11. Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

    Recruiting Phase 3 Caigang Liu Started 2024Primary completion 2026-02 NCT06566755

    cadonilimabbevacizumab

    Genetic testing revealed RAS (including KRAS and NRAS) mutations, or primary sites located in the right half of the colon (including cecum, rising Colon a…

    KRAS G12CKRAS G12DStatus may be outdated, last updated 2024-08-22Colorectal Cancer

  12. Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

    Recruiting Phase 3 Shanghai Kechow Pharma Started 2023Primary completion 2026-12 NCT06008119

    vemurafenib FDA EUbevacizumabcetuximab FDA EU

    Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

    BRAF V600EColorectal Cancer Metastatic

  13. Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

    Active, not recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine Started 2022Primary completion 2026-12 NCT05171660

    sintilimabbevacizumaboxaliplatincapecitabine

    RAS mutation, BRAF V600E wild type, and microsatellite stable

    KRAS G12CKRAS G12DColorectal Cancer Stage IV

  14. Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

    Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2022Primary completion 2028-09 NCT05239741

    pembrolizumab FDA EUoxaliplatinleucovorinfluorouracilirinotecanbevacizumabcetuximab

    …ersus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)

    MSI-H / dMMRColorectal Neoplasms

  15. A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

    Active, not recruiting Phase 3 Pfizer Started 2020Primary completion 2025-03 NCT04607421

    encorafenib FDA EUcetuximab FDA EUoxaliplatinirinotecanleucovorinfluorouracilcapecitabinebevacizumab

    Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation

    BRAF V600ENeoplasms

  16. A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

    Active, not recruiting Phase 3 Bristol Myers Squibb Started 2019Primary completion 2024-08 NCT04008030

    ipilimumab FDA EUoxaliplatinleucovorinfluorouracilirinotecanbevacizumabcetuximabnivolumab FDA EU

    Known tumor microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status per local standard of practice

    MSI-H / dMMRMetastatic Colorectal Cancer

  17. Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

    Active, not recruiting Phase 3 National Cancer Institute (NCI) Started 2018Primary completion 2027-06 NCT02997228

    atezolizumab FDAbevacizumabfluorouracilleucovorinoxaliplatin

    Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) …

    MSI-H / dMMRMetastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7

  18. PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

    Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2026Primary completion 2027-12 NCT07416058

    iparomlimab and tuvonralimabpemetrexedbevacizumab

    these mutations are stratified as follows: EGFR (19del, L858R)

    EGFR exon 19 deletion / L858RKRAS G12CBRAF V600EHER2 (ERBB2) activating mutationALK fusionROS1 fusionRET fusion or mutationLung Adenocarcinoma

  19. Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

    Not yet recruiting Phase 1/2 Innovent Biologics Started 2026Primary completion 2027-06 NCT07612137

    IBI3005sintilimabbevacizumablimertinibosimertinib FDA EUcarboplatin

    Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology speci…

    EGFR exon 19 deletion / L858RSolid Tumor

  20. A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

    Not yet recruiting Phase 2 Anhui Provincial Cancer Hospital Started 2026Primary completion 2029-03 NCT07661173

    furmonertinibpemetrexedcarboplatinbevacizumab

    Confirmed presence of EGFR mutation-positive by tumor histology, cytology, or hematology;

    EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

  21. Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

    Not yet recruiting Phase 1/2 National University Hospital, Singapore Started 2026Primary completion 2028-08 NCT07681297

    tislelizumabbevacizumabcapecitabine

    Patients with driver mutations (e.g., EGFR-mutant or ALK-rearranged NSCLC, HER2+ metastatic breast cancer) must have received at least one …

    EGFR exon 19 deletion / L858RALK fusionAdvanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer

  22. LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

    Not yet recruiting Phase 1/2 Luye Pharma Group Started 2026Primary completion 2028-12 NCT07391566

    LPM6690176bevacizumabFOLFIRIfluorouracilleucovorinirinotecan

    Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;

    KRAS G12CKRAS G12DMetastatic Colorectal Cancer (mCRC)

  23. CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

    Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026Primary completion 2029-12 NCT07383285

    iparomlimab and tuvonralimabcapecitabinebevacizumaboxaliplatin

    The genetic test results were KRAS or NRAS mutations, without BRAF V600 mutations, and the immunohistochemical results were pMMR;

    KRAS G12CKRAS G12DRectal Neoplasms Malignant

  24. A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

    Not yet recruiting Phase 2 Dai, Guanghai Started 2026Primary completion 2029-04 NCT07797244

    XELOXbevacizumab

    RAS-mutant;

    KRAS G12CKRAS G12DAdvanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

  25. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    Recruiting Phase 2 Oncolytics Biotech Started 2026Primary completion 2027-08 NCT07446322

    bevacizumabFOLFIRIPelareorep

    Tumor confirmed to harbor a known RAS mutation per a standard local testing method

    KRAS G12CKRAS G12DRas-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer

  26. Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

    Not yet recruiting Phase 1/2 BOE Technology Group Started 2026Primary completion 2028-04 NCT07551778

    NK CellspemetrexedcetuximabbevacizumabcapecitabineNK cells + PD-(L)1 inhibitor + VEGF inhibitor as first-line maintenance therapy

    …: EGFR sensitive mutations, ALK gene rearrangements, ROS1 mutations, BRAF 600E mutations, KRAS mutations);

    KRAS G12CKRAS G12DNSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)

  27. A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

    Not yet recruiting Phase 2 Yanqiao Zhang Started 2026Primary completion 2027-02 NCT07229846

    AipalolitovorelizumabXELOXbevacizumabFOLFOXIRIoxaliplatinirinotecancapecitabine

    …y confirmed unresectable metastatic colorectal adenocarcinoma of MSS/pMMR type with known BRAF V600E mutation;

    BRAF V600EColorectal Cancer

  28. Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

    Recruiting Phase 2 National Cancer Institute (NCI) Started 2026Primary completion 2029-04 NCT07504588

    Anti-VEGF Monoclonal Antibodybevacizumab FDA EUcarboplatingemcitabinepegylated liposomal doxorubicindoxorubicinsacituzumab govitecan

    Disease must be germline or somatic BRCA1 or BRCA2 mutated or homologous recombination deficiency test positive

    BRCA1/2 mutationRecurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma

  29. A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

    Not yet recruiting Phase 2 Shanghai Chest Hospital Started 2025Primary completion 2026-12 NCT06982924

    limertinibbevacizumab

    Confirmed EGFR - sensitive mutations (Ex19del, L858R) in tumor histology or cytology or in hematology.

    EGFR exon 19 deletion / L858REGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive

  30. Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

    Not yet recruiting Phase 2 Li-kun Chen Started 2025Primary completion 2027-12 NCT07197008

    sacituzumab tirumotecanbevacizumab

    Histologically or cytologically confirmed nonsquamous NSCLC with EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R mutation).

    EGFR exon 19 deletion / L858RLung Cancer

  31. High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

    Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2025Primary completion 2029-12 NCT07182708

    furmonertinibbevacizumab

    EGFR mutation-positive confirmed by local laboratory testing of tissue or blood samples.

    EGFR exon 19 deletion / L858RNSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma

  32. Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

    Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2025Primary completion 2026-12 NCT07007728

    Iparomlimab/Tuvonralimabbevacizumab

    Genetic testing results confirming either RAS mutation or right-sided colon location with RAS wild-type status, absence of BRAF V600E mutation, …

    KRAS G12CKRAS G12DColorectal Neoplasms, Secondary Malignant Neoplasm of Liver

  33. SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

    Not yet recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2025Primary completion 2027-02 NCT06835179

    PD-1 Inhibitorsbevacizumab

    RAS mutation-positive.

    KRAS G12CKRAS G12DUnresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer

  34. XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

    Enrolling by invitation Phase 1/2 Fosun Pharma Started 2025Primary completion 2028-04 NCT06936527

    bevacizumabFOLFOXFOLFIRIDrug: XS-03

    Documentation of RAS mutation.

    KRAS G12CKRAS G12DColorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation

  35. Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

    Recruiting Phase 2 Sun Yat-sen University Started 2025Primary completion 2027-06 NCT07150247

    iparomlimab and tuvonralimabbevacizumabfluorouracilirinotecan

    BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or NGS)

    BRAF V600EBRAF V600 Colorectal Cancer

  36. A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

    Not yet recruiting Phase 2 Vall d'Hebron Institute of Oncology Started 2025Primary completion 2028-02 NCT07178717

    bevacizumabencorafenib FDA EU

    Presence of confirmed BRAF V600E mutation.

    BRAF V600EColo-rectal Cancer

  37. T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

    Recruiting Phase 2 Fudan University Started 2025Primary completion 2027-09 NCT07150208

    bevacizumabtrastuzumab deruxtecan FDA EU

    Histologically confirmed invasive HER2-low expressing breast cancer (specific definition: breast cancer patients with low expression…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer

  38. QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

    Not yet recruiting Phase 2 Qianfoshan Hospital Started 2025Primary completion 2026-06 NCT07009145

    iparomlimab and tuvonralimabbevacizumab

    QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

    MSI-H / dMMRUnresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer

  39. Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

    Recruiting Phase 2 Fudan University Started 2025Primary completion 2027-05 NCT07003022

    cadonilimabbevacizumabregorafenibfruquintinib

    Age 18-80 years. dMMR or MSI-H Diagnosis confirmed by histological examination and/or cytological examination combined w…

    MSI-H / dMMRColo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

  40. Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study

    Active, not recruiting Phase 2 Li-kun Chen Started 2024Primary completion 2028-02 NCT06728865

    befotertinibbevacizumab

    Baseline evaluation confirming the presence of EGFR-sensitizing mutations (19del/L858R) via first- or second-generation sequencing.

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases

  41. Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

    Recruiting Phase 2 Peng Zhang Started 2024Primary completion 2025-12 NCT06755684

    befotertinibbevacizumab

    …ombined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

    EGFR exon 19 deletion / L858REGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed

  42. Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

    Recruiting Phase 2 Fudan University Started 2024Primary completion 2025-12 NCT06218810

    cadonilimabbevacizumabFOLFOX

    RAS mutation;

    KRAS G12CKRAS G12DStatus may be outdated, last updated 2024-01-23Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab

  43. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2028-09 NCT06445062

    daraxonrasibmFOLFOX6bevacizumabmFOLFIRINOXcetuximabgemcitabinenab-paclitaxelzoldonrasibFOLFIRI

    …reatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unre…

    KRAS G12CKRAS G12DColorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC

  44. Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

    Active, not recruiting Phase 2 Cardiff Oncology Started 2024Primary completion 2026-11 NCT06106308

    OnvansertibFOLFIRIbevacizumabFOLFOX

    Documented KRAS or NRAS mutation.

    KRAS G12CKRAS G12DMetastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation

  45. Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

    Recruiting Phase 2 West China Hospital Started 2024Primary completion 2026-04 NCT06341296

    liposomal irinotecanfluorouracilLVbevacizumab

    RAS/BRAF v600e mutant or right half colon cancer is known.

    BRAF V600EStatus may be outdated, last updated 2024-08-12Metastatic Colorectal Cancer

  46. Combination Therapy for BRAF-V600E Metastatic CRCm

    Recruiting Phase 2 Vall d'Hebron Institute of Oncology Started 2024Primary completion 2027-05 NCT06411600

    encorafenib FDA EUcetuximab FDA EUbevacizumab

    Presence of BRAF V600E mutation in tumor tissue previously determined according to the guidelines of each center…

    BRAF V600EMetastatic Colorectal Cancer

  47. Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

    Recruiting Phase 2 Shanghai Changzheng Hospital Started 2024Primary completion 2026-08 NCT06603376

    FOLFIRIvemurafenib FDA EUcetuximab FDA EUbevacizumab

    Patients with BRAFV600E mutation confirmed by tissue or blood testing.

    BRAF V600EStatus may be outdated, last updated 2024-09-19Colorectal Carcinoma

  48. Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

    Recruiting Phase 2 Qilu Hospital of Shandong University Started 2024Primary completion 2026-08 NCT06735326

    fluzoparibbevacizumab FDA EUpaclitaxelcarboplatin

    Confirmed germline BRCA1/2 mutations by professional genetic testing.

    BRCA1/2 mutationOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

  49. Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

    Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2026-11 NCT05266846

    pembrolizumabpemetrexedbevacizumabcisplatin

    Stage IV ALK-rearranged Lung Adenocarcinoma Persistent with 5'ALK Failed from first line Alectinib

    ALK fusionStatus may be outdated, last updated 2024-05-30ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy

  50. Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

    Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2024Primary completion 2026-12 NCT07446452

    disitamab vedotinbevacizumab

    Histologically or cytologically confirmed advanced or recurrent/metastatic HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-).

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)HER2-low Breast Cancer

  51. A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

    Recruiting Phase 2 National Cancer Center, Korea Started 2023Primary completion 2026-09 NCT06156527

    lazertinib FDA EUbevacizumab

    Patients with institutionalized EGFR mutation (exon 19 deletion or L858R)

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2023-12-05Lazertinib

  52. DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

    Recruiting Phase 2 Dizal Pharmaceuticals Started 2023Primary completion 2025-12 NCT06276283

    sunvozertinib FDAbevacizumab

    …A is not limited to a specific EGFR mutation, and Part B only includes patients with EGFR Exon20ins.

    EGFR exon 20 insertionNon-small Cell Lung Cancer

  53. Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

    Recruiting Phase 2 Henan Cancer Hospital Started 2023Primary completion 2028-12 NCT05769010

    trastuzumab rezetecanpyrotinibbevacizumabAdebelizumab

    Pathologically confirmed HER2-positive or HER2-low advanced breast cancer;

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Metastatic Breast Cancer

  54. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    Recruiting Phase 1/2 Parabilis Medicines Started 2023Primary completion 2027-04 NCT05919264

    FOG-001mFOLFOX6leucovorinfluorouraciloxaliplatinnivolumab FDA EUtrifluridine/tipiracilbevacizumab

    MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1/PD-L1

    MSI-H / dMMRCancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor

  55. Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

    Recruiting Phase 2 Sun Yat-sen University Started 2022Primary completion 2025-02 NCT05334277

    furmonertinibpemetrexedcarboplatinbevacizumab

    Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically and confirmed by ctDNA, the r…

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2022-08-31Non-small Cell Lung Cancer

  56. Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

    Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2022Primary completion 2023-10 NCT05503667

    furmonertinibbevacizumab

    …umab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2022-08-17Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation

  57. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    Recruiting Phase 1/2 Genmab Started 2022Primary completion 2027-07 NCT05579366

    rinatabart sesutecancarboplatinbevacizumabpembrolizumaberythromycinitraconazole

    …ncer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negati…

    EGFR exon 19 deletion / L858RBRCA1/2 mutationHigh Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

  58. FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

    Recruiting Phase 2 Sun Yat-sen University Started 2022Primary completion 2026-12 NCT05727163

    dexamethasoneanisodamineoxaliplatinleucovorinfluorouracilirinotecanbevacizumab

    …us Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical S…

    KRAS G12CKRAS G12DBRAF V600EColorectal Cancer Metastatic

  59. Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

    Recruiting Phase 2 ARCAGY/ GINECO GROUP Started 2022Primary completion 2027-02 NCT05183984

    Chemotherapybevacizumab FDA EUniraparib FDA EU

    …ther epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation, c.

    BRCA1/2 mutationOvarian Cancer

  60. Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

    Active, not recruiting Phase 2 Sun Yat-sen University Started 2022Primary completion 2024-08 NCT05491811

    ensartinib FDAbevacizumab

    ALK positive with TP53 mutation was confirmed by tissue samples or blood in each center

    ALK fusionNon-Small Cell Lung Cancer

  61. A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

    Recruiting Phase 1/2 Sanofi Started 2022Primary completion 2027-01 NCT05584670

    SAR445877cetuximabADG126bevacizumabnivolumab FDA EUipilimumab FDA EU

    HCC, colorectal cancer (MSI-H/dMMR), malignant pleural mesothelioma or esophageal squamous cell carcinoma (ESCC). and f…

    MSI-H / dMMRSolid Tumor

  62. Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

    Active, not recruiting Phase 2 Georgetown University Started 2021Primary completion 2026-11 NCT04958811

    tiragolumabatezolizumabbevacizumab

    Confirmed activating alteration in EGFR (cohort B only)

    EGFR exon 19 deletion / L858RNon-squamous Non-small-cell Lung Cancer

  63. Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018Primary completion 2025-02 NCT02971501

    bevacizumabosimertinib FDA EU

    Non-small cell lung cancer (NSCLC) with an activating EGFR mutation (exon 19 deletion, L858R point mutation, or any other mutation known to be associated with EGFR TKI sensiti…

    EGFR exon 19 deletion / L858RMetastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8

  64. Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017Primary completion 2027-07 NCT03181100

    atezolizumab FDAbevacizumabcobimetinib FDA EUnab-paclitaxelpaclitaxelvemurafenib FDA EU

    ADDITIONAL INCLUSION CRITERIA FOR BRAF MUTATION (COHORT 1): Patients with a BRAFV600E mutation being considered for the triplet combination (vemurafenib + cobimetinib + atezol…

    BRAF V600EMetastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8

  65. Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017Primary completion 2028-06 NCT03175432

    atezolizumab FDAbevacizumabcobimetinib FDA EU

    Patients that are known to have BRAFV600 mutation must have received prior BRAFi/MEKi prior to enrolling on TACo.

    BRAF V600EBRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain

  66. A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

    Active, not recruiting Phase 1/2 AstraZeneca Started 2016Primary completion 2021-09 NCT02734004

    olaparib FDA EUdurvalumabbevacizumab FDA EU

    gBRCAm HER2-negative metastatic breast cancer (module 2)

    BRCA1/2 mutationOvarian, Breast, SCLC, Gastric Cancers

  67. A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

    Recruiting Phase 1 Shanghai Junshi Bioscience Started 2025Primary completion 2028-04 NCT06839105

    paclitaxelcisplatincarboplatinpemetrexedoxaliplatincapecitabinebevacizumabRenvastinibAWT020

    Subjects with EGFR or ALK mutations will need to progress with prior treatment with appropriate kinase inhibitors.

    EGFR exon 19 deletion / L858RALK fusionNon-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

  68. JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

    Active, not recruiting Phase 1 Jian Li Started 2025Primary completion 2026-03 NCT06838338

    glecirasibFOLFIRIFOLFOXbevacizumab

    KRAS G12C mutation.

    KRAS G12CColorectal Cancer

  69. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2028-11 NCT06625775

    BBO-10203trastuzumabfulvestrantribociclibFOLFOXbevacizumab

    …-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aN…

    KRAS G12CKRAS G12DPIK3CA activating mutationSolid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

  70. A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

    Active, not recruiting Phase 1 Pfizer Started 2024Primary completion 2026-10 NCT06447662

    PF-07934040gemcitabinenab-paclitaxelcetuximabfluorouraciloxaliplatinleucovorinbevacizumabpembrolizumabpemetrexedcisplatinpaclitaxel

    Documentation of mutated KRAS gene

    KRAS G12DCarcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung

  71. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    Recruiting Phase 1 Bayer Started 2024Primary completion 2027-05 NCT06004245

    VVD-133214pembrolizumab FDA EUbevacizumab

    Have a microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented…

    MSI-H / dMMRAdvanced Solid Tumors, Colorectal Cancer

  72. A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

    Active, not recruiting Phase 1 Sapience Therapeutics Started 2023Primary completion 2026-12 NCT05848739

    ST316FOLFIRIbevacizumab FDA EUfruquintinibtrifluridine/tipiracil

    Subjects with TNBC or OC with known BRCA mutations must have been previously treated with or intolerant to Food and Drug Administration (FDA…

    BRCA1/2 mutationColon Cancer, Metastatic Colon Cancer

  73. First in Human Study of AZD9592 in Solid Tumors

    Active, not recruiting Phase 1 AstraZeneca Started 2022Primary completion 2026-06 NCT05647122

    AZD9592osimertinib FDA EUfluorouracilleucovorinbevacizumab

    Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC

    EGFR exon 19 deletion / L858RAdvanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

  74. AB122 Platform Study

    Recruiting Phase 1 Taiho Pharmaceutical Started 2021Primary completion 2027-06 NCT04999761

    zimberelimabTAS-116futibatinibTAS-115trifluridine/tipiracilramucirumabbevacizumabfluorouracilcisplatinAB154carboplatinnab-paclitaxel

    …ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type. \[Mutant is defined as at least KRAS or NRAS mutant (any exon, any mutation)\].

    KRAS G12CKRAS G12DAdvanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer

  75. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Recruiting Phase 1 AbbVie Started 2021Primary completion 2027-07 NCT05005403

    Azirkitugbudigalimabbevacizumabtelisotuzumab adizutecan

    …essed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Rego…

    BRAF V600ENon-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer

  76. Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

    Active, not recruiting Phase 1 M.D. Anderson Cancer Center Started 2021Primary completion 2027-09 NCT04837716

    bevacizumabcarboplatinensartinib FDApemetrexed

    …arboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

    ALK fusionMetastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

  77. A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

    Active, not recruiting Phase 1 Roche Started 2020Primary completion 2027-12 NCT04449874

    divarasibatezolizumabcetuximabbevacizumaberlotinibGDC-1971inavolisib

    Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.

    KRAS G12CNon-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors

  78. Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

    Active, not recruiting Phase 1 City of Hope Medical Center Started 2020Primary completion 2027-03 NCT04227028

    bevacizumabbrigatinib FDA EU

    …ither primary or metastatic site) diagnosis of locally advanced, recurrent, or metastatic ALK rearranged non-small cell lung cancer (NSCLC)

    ALK fusionLocally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8

  79. CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

    Not yet recruiting Early Phase 1 Second Affiliated Hospital of Nanchang University Started 2024Primary completion 2027-06 NCT06557096

    osimertinib FDA EUbevacizumab

    …tissue samples or blood samples are confirmed to have EGFR-sensitive mutations (including exon 19 deletions or L858R).

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2024-08-16Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer

  80. Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

    Recruiting No phase Second Affiliated Hospital of Nanchang University Started 2026Primary completion 2027-12 NCT07398599

    bevacizumab

    Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

    EGFR exon 19 deletion / L858RLeptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer

  81. Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial

    Not yet recruiting No phase Shanghai Pulmonary Hospital, Shanghai Started 2026Primary completion 2029-07 NCT07870733

    bevacizumabiruplinalkib

    Stage II-III NSCLC per investigator, and ALK-positive.

    ALK fusionALK, NSCLC, Neoadjuvant Therapy

  82. Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

    Recruiting No phase Henan Cancer Hospital Started 2024Primary completion 2025-03 NCT06643000

    furmonertinibbevacizumabpemetrexed

    Genetic testing confirming positive for classical or non-classical EGFR mutations;

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation